Skip to content

Study · Not a test of the peptide alone · 2017

1 result

A novel mechanism of pre-transplant insulin resistance contributing to post-transplant complications: Cyclosporin A-induced O-GlcNAcylation.

Qin X, Li X, Liu C, Chen Z

Biochemical and biophysical research communications19 Aug 2017Cited by 3 (Europe PMC)

PMID28830815 (opens in a new tab)DOI10.1016/j.bbrc.2017.08.033 (opens in a new tab)PepBankPUB-28830815
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Elamipretide (SS-31).

  1. 01LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Mechanism

    In insulin-resistant C2C12 muscle cells, inhibition of ROS production with SS‑31 suppressed O-GlcNAcylation that cyclosporin A had induced.

    In plain wordsIn lab-grown muscle cells, SS‑31 was used as a tool to block ROS and it lowered a protein change caused by cyclosporin A.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseCsA-induced protein O-GlcNAcylation
    Study

    n: not reported in source

    palmitate-induced insulin-resistant C2C12 skeletal muscle cells
    Outcome group
    Receptor activity and mechanism · Metabolic and weight

    Source sentences

    Summary
    inhibition of ROS production with SS-31 suppressed CsA-induced O-GlcNAcylation.
    1 context sentence
    Summary · context
    Thus, in this study, using a cellular model of palmitate-induced insulin resistance, we evaluate the effect of CsA on apoptosis in skeletal muscle C2C12 cells with palmitate-induced insulin resistance.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.